BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fremanezumab (Ajovy) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fremanezumab (Ajovy)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07653516-10615@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Fremanezumab (Ajovy): Phase 4 readout est. (NCT07653516)
DESCRIPTION:Fremanezumab (Ajovy)\, phase 4.\nStudy: Calcitonin Gene-related
  Peptide Antibody in Acute Mountain Sickness\nEstimated primary completion
 : 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/frema
 nezumab-ajovy#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07653516
URL:https://assetmemo.bio/drug/fremanezumab-ajovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832266-10615@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Fremanezumab (Ajovy): Phase 1 readout est. (NCT07832266)
DESCRIPTION:Fremanezumab (Ajovy)\, phase 1.\nStudy: Proactively Intervening
  On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cance
 r: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE 
 RCT)\nEstimated primary completion: 30 September 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/fremanezumab-ajovy#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07832266
URL:https://assetmemo.bio/drug/fremanezumab-ajovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
